Insilico Announces Successful Completion of Phase 0 Microdose Trial and Initiates Phase I Clinical Trial for its First AI-discovered Anti-fibrotic Product Candidate with Novel Target
PR Newswire
February 25, 2022 β 00:00 CST
UNLOCK DATA Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech